Floatz logo

Jcxh-211

Malignant Solid Tumors

Immorna Biotherapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Peg-Rhg-Csf
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4B
DEXAMETHASONE
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Medroxyprogesterone acetate
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Zofran
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B

View all 38 →

Same molecule, other indications

Jcxh-211 is also rated in:

skin neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
Malignant Solid TumorDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →